Commercial Momentum Presentation
Open PDF
| Stock | Control Bionics Ltd (CBL.ASX) |
|---|---|
| Release Time | 4 Jun 2026, 8:27 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Control Bionics Ltd June 2026 Customer Update
Key Points
- US NeuroNode receives dedicated HCPCS code, expanding funding validation
- Signed distribution agreements with Tobii Dynavox and PRC-Saltillo
- Engaged in multiple sports and rehabilitation trials across Australia, US, and International
- Progressing Apple BCI integration for Q3 2026 release
- Expanding research partnerships with leading institutions
Full Summary
Control Bionics Limited (ASX: CBL) provides an update on its commercial momentum and pipeline progress. The company has seen validation of its NeuroNode technology with the award of a dedicated HCPCS code in the US, enabling broader funding validation. New distribution agreements with Tobii Dynavox and PRC-Saltillo have been signed, with funded sales already commencing. Trials and engagements with sports teams, rehabilitation centers, and research institutions in Australia, the US, and International are validating the use of NeuroStrip in various applications. Apple BCI integration is progressing for a Q3 2026 release, and research partnerships with leading institutions are expanding the company's platform opportunities.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In